ReviewFrontiers in immunology2026
Skin barrier dysfunction and correlation with the onset and progression of psoriasis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skin barrier serves as the body's primary line of defense against exogenous insults and is critical for maintaining systemic homeostasis. Emerging evidence indicates that skin barrier dysfunction is not merely a secondary manifestation of psoriasis, but rather an early and pivotal pathogenic driver of the disease. It exerts bidirectional crosstalk with immune dysregulation, genetic predisposition and environmental triggers, collectively contributing to the initiation and progression of psoriasis. This review first elaborates on the normal structural composition and physiological functions of the skin barrier, followed by a discussion of the major etiological factors of psoriasis and the underlying mechanisms by which barrier impairment promotes psoriasis pathogenesis. These mechanisms include aberrant keratinocyte hyperproliferation, abnormal expression of structural proteins, tight junction disruption, aquaporin 3 dysfunction and dysregulated cutaneous lipid metabolism. Furthermore, we highlight the clinical significance of skin barrier restoration in psoriasis management and propose directions for future research. Elucidating the intricate crosstalk between skin barrier dysfunction and psoriasis pathogenesis will facilitate the identification of novel diagnostic biomarkers and the development of targeted therapeutic strategies for this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.